JP2017513915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513915A5 JP2017513915A5 JP2016565050A JP2016565050A JP2017513915A5 JP 2017513915 A5 JP2017513915 A5 JP 2017513915A5 JP 2016565050 A JP2016565050 A JP 2016565050A JP 2016565050 A JP2016565050 A JP 2016565050A JP 2017513915 A5 JP2017513915 A5 JP 2017513915A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- butyl
- substituent
- heteroaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- -1 methoxy, ethoxy, propoxy, isopropoxy Chemical group 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 3
- 125000005215 cycloalkylheteroaryl group Chemical group 0.000 description 3
- 150000005347 biaryls Chemical group 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166547.1 | 2014-04-30 | ||
| EP14166547.1A EP2940022B1 (en) | 2014-04-30 | 2014-04-30 | Furopyridines as inhibitors of protein kinases |
| PCT/CZ2015/000038 WO2015165428A1 (en) | 2014-04-30 | 2015-04-29 | Furopyridines as inhibitors of protein kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513915A JP2017513915A (ja) | 2017-06-01 |
| JP2017513915A5 true JP2017513915A5 (enExample) | 2018-07-12 |
| JP6386585B2 JP6386585B2 (ja) | 2018-09-05 |
Family
ID=50679866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565050A Active JP6386585B2 (ja) | 2014-04-30 | 2015-04-29 | プロテインキナーゼのインヒビターとしてのフロピリジン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9902733B2 (enExample) |
| EP (1) | EP2940022B1 (enExample) |
| JP (1) | JP6386585B2 (enExample) |
| WO (1) | WO2015165428A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107216334A (zh) * | 2017-06-29 | 2017-09-29 | 上海吉尔多肽有限公司 | 一种6‑氯呋喃[3,2‑b]吡啶的合成方法 |
| US20250002507A1 (en) | 2021-10-14 | 2025-01-02 | Vanderbilt University | 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2023220435A1 (en) * | 2022-05-12 | 2023-11-16 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| EP4353727A1 (en) | 2022-10-13 | 2024-04-17 | Masarykova Univerzita | Substituted furopyridines for therapeutic use |
| WO2024251187A1 (en) * | 2023-06-06 | 2024-12-12 | Beigene, Ltd. | Benzofuran derivatives as sik inhibitors and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732969B1 (fr) * | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2263566C (en) | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
| US20010007867A1 (en) * | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6696439B1 (en) * | 1999-02-26 | 2004-02-24 | Eli Lilly And Company | 5-HT1F agonists |
| PL350864A1 (en) * | 1999-02-26 | 2003-02-10 | Lilly Co Eli | 5-ht1f |
| JPWO2005023771A1 (ja) * | 2003-09-05 | 2006-11-02 | 小野薬品工業株式会社 | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| CN1878773A (zh) * | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
| EP1696915A1 (en) * | 2003-12-19 | 2006-09-06 | Pfizer, Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| WO2011138657A1 (en) * | 2010-05-04 | 2011-11-10 | Glenmark Pharmaceuticals S.A. | Aryl substituted olefinic compounds as pde10a inhibitors |
-
2014
- 2014-04-30 EP EP14166547.1A patent/EP2940022B1/en active Active
-
2015
- 2015-04-29 US US15/304,043 patent/US9902733B2/en active Active
- 2015-04-29 WO PCT/CZ2015/000038 patent/WO2015165428A1/en not_active Ceased
- 2015-04-29 JP JP2016565050A patent/JP6386585B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513915A5 (enExample) | ||
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| JP2019524883A5 (enExample) | ||
| RU2015147447A (ru) | Производные доластатина 10 и ауристатинов | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| JP2015531773A5 (enExample) | ||
| JP2016519072A5 (enExample) | ||
| JP2014514290A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| RU2015100901A (ru) | Производные эфира гетероарилкарбоновой кислоты | |
| JP2014520108A5 (enExample) | ||
| JP2017533263A5 (enExample) | ||
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2013537240A5 (enExample) | ||
| MY197742A (en) | Morphinan derivative | |
| WO2012047630A2 (en) | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use | |
| JP2018507230A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| BR112013017416A2 (pt) | derivado de indola ou indazola ou sal do mesmo | |
| JP2016523830A5 (enExample) | ||
| KR20250141267A (ko) | 개선된 특성을 가지는 테트라진 | |
| Li et al. | Synthesis, structure–activity relationship and biological evaluation of novel nitrogen mustard sophoridinic acid derivatives as potential anticancer agents | |
| RU2017108909A (ru) | Производные изохинолинона, полезные для лечения рака | |
| Hansen et al. | The importance of correct tautomeric structures for biological molecules | |
| EP4034106A1 (en) | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |